UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
Current Report
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
(Exact name of Registrant as Specified in Its Charter)
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| |
Not Applicable | |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s Telephone Number, Including Area Code: +
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading |
Name of each exchange | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
| Item 5.07. | Submission of Matters to a Vote of Security Holders. |
On June 11, 2025, Mural Oncology plc (the “Company”) held its 2025 annual general meeting (the “AGM”). Below are the voting results for the proposals submitted to the Company’s shareholders for a vote at the AGM.
PROPOSAL 1. – ELECTION OF DIRECTORS
In accordance with the Company’s Constitution, as amended, the Company’s shareholders elected, by separate resolutions, six directors to serve until the Company’s 2026 annual general meeting, as set forth below:
| Director Nominees |
For | Against | Abstain | Broker Non-Votes | ||||||||||||
| Francis Cuss, M.B., B.Chir., FRCP |
5,883,909 | 596,030 | 2,488 | 5,657,632 | ||||||||||||
| George Golumbeski, Ph.D. |
5,713,441 | 764,765 | 4,221 | 5,657,632 | ||||||||||||
| Benjamin Hickey, MBA |
5,884,908 | 594,065 | 3,454 | 5,657,632 | ||||||||||||
| Scott Jackson, MBA |
5,879,630 | 601,008 | 1,789 | 5,657,632 | ||||||||||||
| Caroline Loew, Ph.D. |
5,886,901 | 614,239 | 1,287 | 5,657,632 | ||||||||||||
| Sachiyo Minegishi, MBA |
5,883,528 | 593,623 | 5,276 | 5,657,632 | ||||||||||||
PROPOSAL 2. – RATIFICATION OF SELECTION OF INDEPENDENT AUDITOR
The Company’s shareholders ratified, in a non-binding vote, the selection of PricewaterhouseCoopers LLP as the Company’s independent auditor for the fiscal year ending December 31, 2025 and authorized, in a binding vote, the Company’s board of directors, acting through the audit committee, to set the independent auditor’s remuneration, as set forth below:
| For |
Against |
Abstain |
Broker Non-Votes | |||
| 11,918,446 | 190,443 | 31,171 | — |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Mural Oncology plc | ||||||
| Dated: June 12, 2025 | By: | /s/ Maiken Keson-Brookes | ||||
| Name: | Maiken Keson-Brookes | |||||
| Title: | Chief Legal Officer | |||||